申请人:Novo Nordisk A/S
公开号:US05075304A1
公开(公告)日:1991-12-24
New imidazoquinoxaline compounds having the general formula ##STR1## wherein R.sup.3 is ##STR2## or CO.sub.2 R' wherein R' is C.sub.3-7 -cycloalkyl; R.sup.5 is methyl, which is substituted with hydrogen, alkoxycarbonyl, heteroaryl, morpholino, C.sub.3-7 -cycloalkyl, C.sub.1-6 -alkenyl, arylacyl, alkylacyl, alkoxyalkyl, alkoxy, phthalimidophenyl, aralkyl or aryl, all of which are substituted with hydrogen, halogen, C.sub.1-6 -alkyl, amino, azido, or C.sub.1-6 -alkoxy; and R.sup.6 is H, C.sub.1-6 -alkyl, halogen, or CF.sub.3. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and in improving the cognitive function of the brain of mammals.
新的咪唑喹啉类化合物具有一般式##STR1##其中R.sup.3是##STR2##或CO.sub.2R',其中R'是C.sub.3-7-环烷基;R.sup.5是甲基,其被氢,烷氧羰基,杂环芳基,吗啉基,C.sub.3-7-环烷基,C.sub.1-6-烯基,芳基酰基,烷基酰基,烷氧基烷基,烷氧基,邻苯二甲酰苯基,芳基甲基或芳基取代,所有这些都被氢,卤素,C.sub.1-6-烷基,氨基,偶氮基或C.sub.1-6-烷氧基取代;R.sup.6是H,C.sub.1-6-烷基,卤素或CF.sub.3。这些化合物在精神药物制剂中用作抗癫痫药、抗焦虑药、催眠药,以及改善哺乳动物大脑认知功能。